Abstract
ABSTRACT This study analyzed functions of miR-34a and SIRT1 in modulating efficacy of Olaparib in pancreatic cancer in vitro. RNA expressions of miR-34a and SIRT1 were evaluated through RT-qPCR in HPDE6-C7, SW1990, PANC-1 and MIA PaCa-2 cells. MiR-34a was promoted in cancer cell lines while SIRT1 was decreased. Luciferase reporter assay verified bindings between miR-34a and SIRT1. Moreover, E-cadherin was promoted by miR-34a mimics and SIRT1 suppression while N-cadherin and Vimentin were both downregulated. Additionally, PARP1 protein expression was increased after miR- 34a promotion and SIRT1 downregulation. Besides that, PARP1 protein levels and EMT were significantly inhibited after treated by Olaparib (0, 0.5, 1 and 1.5ìM). In Olaparib-treated cancer cells, SIRT1, PARP1 and EMT were all distinctly decreased after SIRT1 suppression and overexpression of miR-34a induced much lower level of SIRT1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
